• Je něco špatně v tomto záznamu ?

Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial

R. Koch, L. Haveman, R. Ladenstein, B. Brichard, H. Jürgens, S. Cyprova, H. van den Berg, W. Hassenpflug, A. Raciborska, T. Ek, D. Baumhoer, G. Egerer, L. Kager, M. Renard, P. Hauser, S. Burdach, JVMG. Bovee, AM. Hong, P. Reichardt, J. Kruseova,...

. 2023 ; 29 (24) : 5057-5068. [pub] 2023Dec15

Jazyk angličtina Země Spojené státy americké

Typ dokumentu randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze III, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000230

Grantová podpora
108128 Deutsche Krebshilfe (German Cancer Aid)
10112018 Deutsche Krebshilfe (German Cancer Aid)
01GM0869 Bundesministerium für Bildung und Forschung (BMBF)
01KD2207A Bundesministerium für Bildung und Forschung (BMBF)
01KT1310 Bundesministerium für Bildung und Forschung (BMBF)

PURPOSE: The phase III, open-label, prospective, multicenter, randomized Ewing 2008R1 trial (EudraCT2008-003658-13) was conducted in 12 countries to evaluate the effect of zoledronic acid (ZOL) maintenance therapy compared with no add-on regarding event-free survival (EFS, primary endpoint) and overall survival (OS) in standard-risk Ewing sarcoma (EWS). PATIENTS AND METHODS: Eligible patients had localized EWS with either good histologic response to induction chemotherapy and/or small tumors (<200 mL). Patients received six cycles of VIDE induction and eight cycles of VAI (male) or eight cycles of VAC (female) consolidation. ZOL treatment started parallel to the sixth consolidation cycle. Randomization was stratified by tumor site (pelvis/other). The two-sided adaptive inverse-normal four-stage design (planned sample size 448 patients, significance level 5%, power 80%) was changed after the first interim analysis using the Müller-Schäfer method. RESULTS: Between April 2010 and November 2018, 284 patients were randomized (142 ZOL/142 no add-on). With a median follow-up of 3.9 years, EFS was not significantly different between ZOL and no add-on group in the adaptive design (HR, 0.74; 95% CI, 0.43-1.28, P = 0.27, intention-to-treat). Three-year EFS rates were 84.0% (95% CI, 77.7%-90.8%) for ZOL vs. 81.7% (95% CI, 75.2%-88.8%) for no add-on. Results were similar in the per-protocol collective. OS was not different between groups. The 3-year OS was 92.8% (95% CI, 88.4%-97.5%) for ZOL and 94.6% (95% CI, 90.9%-98.6%) for no add-on. Noticeable more renal, neurologic, and gastrointestinal toxicities were observed for ZOL (P < 0.05). Severe renal toxicities occurred more often in the ZOL arm (P = 0.003). CONCLUSIONS: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.

2nd Dept of Pediatrics Semmelweis University Budapest Hungary

Amsterdam UMC location University of Amsterdam Emma Children's Hospital Department of pediatric oncology Amsterdam the Netherlands

Bone Tumor Reference Center at the Institute of Medical Genetics and Pathology University Hospital Basel and University of Basel Switzerland

Center for Pediatric Oncology and Hematology Vilnius University Hospital Santaros Klinikos Vilnius Lithuania

Central Clinical School Faculty of Medicine and Health The University of Sydney Sydney Australia

Centre for Clinical Trials Muenster University of Muenster Muenster Germany

Charles University Motol Children's Hospital Prague Czech Republic

Childhood Cancer Center Queen Silvia Children's Hospital Gothenburg Sweden

Cliniques Universitaires Saint Luc Department of Pediatric Haematology and Oncology Université Catholique de Louvain Brussels Belgium

Comprehensive Cancer Center Erlangen EMN Erlangen Germany

Department of Clinical Radiology Klinikum Ibbenbüren Ibbenburen Germany

Department of Internal Medicine 5 Heidelberg University Hospital Heidelberg Germany

Department of Medical Oncology Chris O'Brien Lifehouse Sydney Australia

Department of Medical Oncology Leiden University Medical Center Leiden the Netherlands

Department of Medical Oncology Sarcoma Center University of Duisburg Essen Essen Germany

Department of Medicine A Hematology Oncology and Pneumology University Hospital Muenster Muenster Germany

Department of Oncology and Hematology University Children's Hospital Basel Basel Switzerland

Department of Oncology and Palliative Care Helios Klinikum Berlin Buch Berlin Germany

Department of Orthopaedics Semmelweis University Budapest Hungary

Department of Orthopedic Oncology University Hospital Essen Essen Germany

Department of Paediatrics Medical University of Vienna Vienna Austria

Department of Particle Therapy University Hospital Essen West German Proton Therapy Centre Essen Essen Germany

Department of Pathology Leiden University Medical Center Leiden the Netherlands

Department of Pediatric Hematology and Oncology University Children's Hospital Muenster Germany

Department of Pediatric Hematology Oncology and Hematopoietic Stem Cell Transplantation Princess Elisabeth Children's Hospital Ghent University Ghent Belgium

Department of Pediatrics and Children's Cancer Research Center Technische Universität München Munich Germany

Department of Pediatrics University Hospital Erlangen Erlangen Germany

Department of Radiation Oncology Chris O'Brien Lifehouse Camperdown Australia

Department of Solid tumors Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

Division of Hematology Oncology and Stem Cell Transplantation New Children's Hospital Helsinki University Hospital University of Helsinki Helsinki Finland

Division of Translational Pathology Gerhard Domagk Institute of Pathology University Hospital Muenster Muenster Germany

Douglass Hanly Moir Pathology Notre Dame Medical School Royal Prince Alfred Hospital Sydney Australia

Faculty of Medicine and Health University of Sydney Sydney Australia

General Pediatrics Oncology and Hematology Vestische Kinder und Jugendklinik Datteln Witten Herdecke University Datteln Germany

German Consortium for Translational Cancer Research German Cancer Research Centre Essen Germany

Institute of Biostatistics and Clinical Research University of Muenster Germany

Institute of Clinical Medicine Vilnius University Vilnius Lithuania

Lund University Skane University Hospital Department of Clinical Sciences Lund Neurology Lund Sweden

Mother and Child Institute Department of Oncology and Surgical Oncology for Children and Youth Warsaw Poland

Paediatrics 3 University Hospital Essen Essen Germany

Pediatric Hematology and Oncology University Hospital Eppendorf Hamburg Germany

Pediatric Hematology and Oncology University Hospital Leuven Gasthuisberg Leuven Belgium

Pediatric Oncology and Transplantation Unit Velkey László Child's Health Center Borsod Abaúj Zemplén County University Teaching Hospital Miskolc Hungary

St Anna Children's Hospital and Children's Cancer Research Institute

Studies and Statistics for Integrated Research and Projects St Anna Children's Hospital Department of Paediatrics and Children's Cancer Research Institute Medical University of Vienna Vienna Austria

West German Cancer Centre Network Essen and Muenster Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000230
003      
CZ-PrNML
005      
20240223082850.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-23-1966 $2 doi
035    __
$a (PubMed)37843857
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Koch, Raphael $u Institute of Biostatistics and Clinical Research, University of Muenster, Germany $1 https://orcid.org/0000000255815122
245    10
$a Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial / $c R. Koch, L. Haveman, R. Ladenstein, B. Brichard, H. Jürgens, S. Cyprova, H. van den Berg, W. Hassenpflug, A. Raciborska, T. Ek, D. Baumhoer, G. Egerer, L. Kager, M. Renard, P. Hauser, S. Burdach, JVMG. Bovee, AM. Hong, P. Reichardt, J. Kruseova, A. Streitbürger, T. Kühne, T. Kessler, M. Bernkopf, T. Butterfaß-Bahloul, C. Dhooge, S. Bauer, J. Kiss, M. Paulussen, F. Bonar, A. Ranft, B. Timmermann, J. Rascon, V. Vieth, J. Kanerva, A. Faldum, W. Hartmann, L. Hjorth, VA. Bhadri, M. Metzler, H. Gelderblom, U. Dirksen
520    9_
$a PURPOSE: The phase III, open-label, prospective, multicenter, randomized Ewing 2008R1 trial (EudraCT2008-003658-13) was conducted in 12 countries to evaluate the effect of zoledronic acid (ZOL) maintenance therapy compared with no add-on regarding event-free survival (EFS, primary endpoint) and overall survival (OS) in standard-risk Ewing sarcoma (EWS). PATIENTS AND METHODS: Eligible patients had localized EWS with either good histologic response to induction chemotherapy and/or small tumors (<200 mL). Patients received six cycles of VIDE induction and eight cycles of VAI (male) or eight cycles of VAC (female) consolidation. ZOL treatment started parallel to the sixth consolidation cycle. Randomization was stratified by tumor site (pelvis/other). The two-sided adaptive inverse-normal four-stage design (planned sample size 448 patients, significance level 5%, power 80%) was changed after the first interim analysis using the Müller-Schäfer method. RESULTS: Between April 2010 and November 2018, 284 patients were randomized (142 ZOL/142 no add-on). With a median follow-up of 3.9 years, EFS was not significantly different between ZOL and no add-on group in the adaptive design (HR, 0.74; 95% CI, 0.43-1.28, P = 0.27, intention-to-treat). Three-year EFS rates were 84.0% (95% CI, 77.7%-90.8%) for ZOL vs. 81.7% (95% CI, 75.2%-88.8%) for no add-on. Results were similar in the per-protocol collective. OS was not different between groups. The 3-year OS was 92.8% (95% CI, 88.4%-97.5%) for ZOL and 94.6% (95% CI, 90.9%-98.6%) for no add-on. Noticeable more renal, neurologic, and gastrointestinal toxicities were observed for ZOL (P < 0.05). Severe renal toxicities occurred more often in the ZOL arm (P = 0.003). CONCLUSIONS: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a Ewingův sarkom $x patologie $7 D012512
650    _2
$a kyselina zoledronová $x terapeutické užití $7 D000077211
650    _2
$a prospektivní studie $7 D011446
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
650    12
$a nádory kostí $x patologie $7 D001859
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Haveman, Lianne $u Department of Solid tumors, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $1 https://orcid.org/0000000185198906
700    1_
$a Ladenstein, Ruth $u Studies and Statistics for Integrated Research and Projects, St. Anna Children's Hospital, Department of Paediatrics and Children's Cancer Research Institute (CCRI), Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000165483873
700    1_
$a Brichard, Benedicte $u Cliniques Universitaires Saint Luc, Department of Pediatric Haematology and Oncology, Université Catholique de Louvain, Brussels, Belgium $1 https://orcid.org/0000000327651711
700    1_
$a Jürgens, Heribert $u Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Germany $1 https://orcid.org/0009000216340942
700    1_
$a Cyprová, Soňa $u Charles University, Motol Children's Hospital, Prague, Czech Republic $1 https://orcid.org/0009000279018432 $7 xx0314248
700    1_
$a van den Berg, Henk $u Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, Department of pediatric oncology, Amsterdam, the Netherlands $1 https://orcid.org/0009000214372895
700    1_
$a Hassenpflug, Wolf $u Pediatric Hematology and Oncology, University Hospital Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000242305828
700    1_
$a Raciborska, Anna $u Mother and Child Institute, Department of Oncology and Surgical Oncology for Children and Youth, Warsaw, Poland $1 https://orcid.org/0000000326127934
700    1_
$a Ek, Torben $u Childhood Cancer Center, Queen Silvia Children's Hospital, Gothenburg, Sweden $1 https://orcid.org/000000020518983X
700    1_
$a Baumhoer, Daniel $u Bone Tumor Reference Center at the Institute of Medical Genetics and Pathology, University Hospital Basel and University of Basel, Switzerland $1 https://orcid.org/0000000221377507
700    1_
$a Egerer, Gerlinde $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany $1 https://orcid.org/0009000504624165
700    1_
$a Kager, Leo $u St Anna Children's Hospital and Children's Cancer Research Institute; Department of Paediatrics, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000349546488
700    1_
$a Renard, Marleen $u Pediatric Hematology and Oncology, University Hospital Leuven Gasthuisberg, Leuven, Belgium $1 https://orcid.org/0000000201147560
700    1_
$a Hauser, Peter $u Pediatric Oncology and Transplantation Unit, Velkey László Child's Health Center, Borsod-Abaúj-Zemplén County University Teaching Hospital, Miskolc, Hungary $u 2nd Dept of Pediatrics, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000283078975
700    1_
$a Burdach, Stefan $u Department of Pediatrics and Children's Cancer Research Center (CCRC), Technische Universität München, Munich, Germany $1 https://orcid.org/0000000164004471
700    1_
$a Bovee, Judith V M G $u Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands $1 https://orcid.org/0000000311550481
700    1_
$a Hong, Angela M $u Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, Australia $u Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia $1 https://orcid.org/000000033668243X
700    1_
$a Reichardt, Peter $u Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany $1 https://orcid.org/0009000814103111
700    1_
$a Kruseova, Jarmila $u Charles University, Motol Children's Hospital, Prague, Czech Republic $1 https://orcid.org/0000000265767048
700    1_
$a Streitbürger, Arne $u Department of Orthopedic Oncology, University Hospital Essen, Essen, Germany $1 https://orcid.org/0009000679432579
700    1_
$a Kühne, Thomas $u Department of Oncology and Hematology, University Children's Hospital Basel, Basel, Switzerland $1 https://orcid.org/0000000273877028
700    1_
$a Kessler, Torsten $u Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany $1 https://orcid.org/0000000176795362
700    1_
$a Bernkopf, Marie $u St Anna Children's Hospital and Children's Cancer Research Institute; Department of Paediatrics, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000166504592
700    1_
$a Butterfaß-Bahloul, Trude $u Centre for Clinical Trials (ZKS) Muenster, University of Muenster, Muenster, Germany $1 https://orcid.org/0009000901046653
700    1_
$a Dhooge, Catharina $u Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Princess Elisabeth Children's Hospital, Ghent University, Ghent, Belgium $1 https://orcid.org/0000000299403672
700    1_
$a Bauer, Sebastian $u Department of Medical Oncology, Sarcoma Center, University of Duisburg-Essen, Essen, Germany $u West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany $1 https://orcid.org/0000000159498120
700    1_
$a Kiss, János $u Department of Orthopaedics, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0009000683712557
700    1_
$a Paulussen, Michael $u General Pediatrics, Oncology and Hematology, Vestische Kinder- und Jugendklinik Datteln, Witten/Herdecke University, Datteln, Germany $1 https://orcid.org/0009000725346381
700    1_
$a Bonar, Fiona $u Douglass Hanly Moir Pathology, Notre Dame Medical School, Royal Prince Alfred Hospital, Sydney, Australia $1 https://orcid.org/0000000168253336
700    1_
$a Ranft, Andreas $u West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany $u Paediatrics III, University Hospital Essen, Essen, Germany $u German Consortium for Translational Cancer Research (DKTK), German Cancer Research Centre, Essen, Germany $1 https://orcid.org/0000000344247569
700    1_
$a Timmermann, Beate $u West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany $u German Consortium for Translational Cancer Research (DKTK), German Cancer Research Centre, Essen, Germany $u Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), Essen, Germany $1 https://orcid.org/0000000322742008
700    1_
$a Rascon, Jelena $u Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania $u Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania $1 https://orcid.org/0000000344206943
700    1_
$a Vieth, Volker $u Department of Clinical Radiology, Klinikum Ibbenbüren, Ibbenburen, Germany $1 https://orcid.org/0009000775413116
700    1_
$a Kanerva, Jukka $u Division of Hematology-Oncology and Stem Cell Transplantation, New Children's Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland $1 https://orcid.org/0000000258396058
700    1_
$a Faldum, Andreas $u Institute of Biostatistics and Clinical Research, University of Muenster, Germany $1 https://orcid.org/0000000226748098
700    1_
$a Hartmann, Wolfgang $u Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, Muenster, Germany $1 https://orcid.org/0000000276095021
700    1_
$a Hjorth, Lars $u Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden $1 https://orcid.org/0000000283027174
700    1_
$a Bhadri, Vivek A $u Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia $u Faculty of Medicine and Health, University of Sydney, Sydney, Australia $1 https://orcid.org/0000000298142060
700    1_
$a Metzler, Markus $u Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany $u Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany $1 https://orcid.org/0000000245231676
700    1_
$a Gelderblom, Hans $u Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands $1 https://orcid.org/0000000192708636
700    1_
$a Dirksen, Uta $u West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany $u Paediatrics III, University Hospital Essen, Essen, Germany $u German Consortium for Translational Cancer Research (DKTK), German Cancer Research Centre, Essen, Germany $1 https://orcid.org/0000000254357860
773    0_
$w MED00001121 $t Clinical cancer research $x 1557-3265 $g Roč. 29, č. 24 (2023), s. 5057-5068
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37843857 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240223082843 $b ABA008
999    __
$a ok $b bmc $g 2049108 $s 1209924
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 29 $c 24 $d 5057-5068 $e 2023Dec15 $i 1557-3265 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
GRA    __
$a 108128 $p Deutsche Krebshilfe (German Cancer Aid)
GRA    __
$a 10112018 $p Deutsche Krebshilfe (German Cancer Aid)
GRA    __
$a 01GM0869 $p Bundesministerium für Bildung und Forschung (BMBF)
GRA    __
$a 01KD2207A $p Bundesministerium für Bildung und Forschung (BMBF)
GRA    __
$a 01KT1310 $p Bundesministerium für Bildung und Forschung (BMBF)
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace